Abstract
Abstract
Purpose
Chordomas are malignant tumors that destroy bones, compress surrounding nerve tissues and exhibit phenotypes that recapitulate notochordal differentiation in the axial skeleton. Chordomas recur frequently, as they resist radio-chemotherapy and are difficult to completely resect, leading to repeated bone destruction and local expansion via unknown mechanisms. Here, using chordoma specimens and JHC7 chordoma cells, we asked whether chordoma cells possess bone-dissolving activity.
Methods
CT imaging and histological analysis were performed to evaluate the structure and mineral density of chordoma-invaded bone and osteolytic marker expression. JHC7 cells were subjected to immunocytochemistry, imaging of cell fusion, calcium dynamics and acidic vacuoles, and bone lysis assays.
Results
In patients, we found that the skull base invaded by chordoma was highly porous, showed low mineral density and contained brachyury-positive chordoma cells and conventional osteoclasts both expressing the osteolytic markers tartrate-resistant acid phosphatase (TRAP) and collagenases. JHC7 cells expressed TRAP and cathepsin K, became multinucleated via cell-cell fusion, showed spontaneous calcium oscillation, and were partly responsive to the osteoclastogenic cytokine RANKL. JHC7 cells exhibited large acidic vacuoles, and nonregulatory bone degradation without forming actin rings. Finally, bone-derived factors, calcium ions, TGF-β1, and IGF-1 enhanced JHC7 cell proliferation.
Conclusion
In chordoma, we propose that in addition to conventional bone resorption by osteoclasts, chordoma cells possess bone-dissolving activity at the tumor-bone boundary. Furthermore, bone destruction and tumor expansion may occur in a positive feedback loop.
Funder
Japan Society for the Promotion of Science
Keio University Sakaguchi-Memorial Medical Science Fund
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. M.L. McMaster, A.M. Goldstein, C.M. Bromley, N. Ishibe, D.M. Parry, Cancer causes control. 12, 1–11 (2001)
2. S.H. Bakker, W.C.H. Jacobs, W. Pondaag, H. Gelderblom, R.A. Nout, P.D.S. Dijkstra, W.C. Peul, C.L.A. Vleggeert-Lankamp, Eur. Spine J. 27, 3043–3058 (2018). https://doi.org/10.1007/s00586-018-5764-0
3. O.D.P. Tirabosco, R. Yamaguchi, T., Conventional Chordoma, 5th edn. (World Health Organization, International Agency for Research on Cancer, 2020), pp. 451–453
4. S. Vujovic, S. Henderson, N. Presneau, E. Odell, T.S. Jacques, R. Tirabosco, C. Boshoff, A.M. Flanagan, J. Pathol. 209, 157–165 (2006). https://doi.org/10.1002/path.1969
5. X. Sun, F. Hornicek, J.H. Schwab, Curr. Rev. Musculoskelet. Med. 8, 344–352 (2015). https://doi.org/10.1007/s12178-015-9311-x